Navigation Links
YMed, Inc. Successfully Completes First Clinical Cases With Innovative VascuTraK(TM) II PTA Dilatation Catheter
Date:12/10/2007

SAN DIEGO, Dec. 10 /PRNewswire/ -- YMed, Inc. announced today that it has successfully completed its first U.S. cases with its proprietary VascuTraK(TM) II PTA Dilatation Catheter. The VascuTraK(TM) II PTA Catheter is a unique 5F compatible, single operator rapid exchange system.

YMed's VascuTraK(TM) II catheter is designed and indicated for vascular intervention of a wide range of peripheral arteries including the treatment of obstructive lesions of native or synthetic arteriovenous dialysis fistulae.

"The VascuTraK(TM) II catheter is an important advancement in technology for the treatment of patients with peripheral vascular disease (PVD), especially below the knee where amputation risks are the greatest," says Dr. Rajesh Dave, Chairman, Endovascular Medicine, Harrisburg Hospital, Harrisburg, PA. Dr. Dave performed the initial clinical cases with commercially available VascuTraK(TM) II catheters. He noted that in some lesion subsets, including calcified lesions involving the popliteal artery, the VascuTraK(TM) II catheter was sufficient to complete the intervention without adjunctive devices that may increase restenois or require further intervention.

YMed plans to initiate U.S. Sales with a broad range of VascuTraK(TM) II PTA dilatation catheters during Q1 2008, says Richard Cooper, Vice President Sales & Marketing, YMed, Inc. "The VascuTraK(TM) II is the first PTA dilatation catheter to combine the features of plaque modification and longer balloon lengths," Mr. Cooper added. Balloon diameters range from 2.0 mm to 4.0 mm in 0.5 mm increments with balloon lengths of 20 mm to 120 mm.

YMed, Inc. is a privately held Corporation established in 2004. The company was founded and is managed by a highly experienced, multinational team of medical, engineering and business professionals from within the cardio and peripheral vascular industry. This team develops, manufactures and markets innovative products for vascular intervention providing less invasive therapy for a broad range of circulatory diseases.


'/>"/>
SOURCE YMed, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Related medicine technology :

1. Harvard Medical School-Partners HealthCare Center for Genetics and Genomics Successfully Completes Evaluation of AutoGenomics 2C9-VKORC1 Panel to Assess Warfarin Sensitivity
2. TaiGen Biotechnology Successfully Completes Patient Recruitment for Phase II Trial of Nemonoxacin for Treatment of Adult Community Acquired Pneumonia (CAP)
3. Harvard Medical School-Partners HealthCare Center for Genetics and Genomics Successfully Completes Evaluation of AutoGenomics 2C9-VKORC1 Panel to Assess Warfarin Sensitivity
4. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
5. TorreyPines Therapeutics Completes Patient Enrollment in Phase IIb Clinical Trial of Tezampanel for the Treatment of Acute Migraine Headache
6. QuatRx Completes Patient Enrollment in Phase 3 Study of Ophena(TM) in Women with Postmenopausal Vaginal Syndrome
7. CryoCor Completes Enrollment of Pivotal Clinical Study for Atrial Fibrillation
8. Anesiva Completes Enrollment in Phase 3 Clinical Trial of Zingo(TM) to Treat Pain Associated With Venous Access Procedures in Adults
9. Human Genome Sciences Completes Enrollment of First Phase 3 Albuferon(R) Trial Ahead of Schedule
10. Cadence Pharmaceuticals Completes Enrollment of Pivotal Phase III Trial for Intravenous Acetaminophen Ahead of Schedule
11. TorreyPines Therapeutics Completes Phase I Multiple Dose Clinical Trial of NGX267, a Selective M1 Agonist for the Potential Treatment of Cognitive Impairment Associated with Schizophrenia
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/28/2017)... Sept. 28, 2017 Hill-Rom Holdings, Inc. (NYSE: ... conference call and webcast on Friday, November 3, 2017, ... and ending at approximately 8:30 a.m. (CDT) / 9:30 ... company,s 2017 financial performance and guidance for 2018, Hill-Rom ... to enhance operational performance, and long-range financial outlook through ...
(Date:9/27/2017)... NEW YORK , Sept. 27, 2017  DarioHealth Corp. (NASDAQ: ... data solutions, today announced that its MyDario product is expected to appear ... listings for when The Dr. Oz Show airs in your area: ... The nine-time Emmy award-winning, The ... ...
(Date:9/23/2017)... , Sept. 22, 2017 Janssen Biotech, Inc. ... response letter from the U.S. Food and Drug Administration ... of sirukumab for the treatment of moderately to severely ... additional clinical data are needed to further evaluate the ... severely active RA. ...
Breaking Medicine Technology:
(Date:10/13/2017)... ... October 13, 2017 , ... Ellevate Network, the leading network ... advocate for action towards gender equality at their inaugural Summit in New York City ... and reached a social audience of over 3 million. To watch the Mobilize Women ...
(Date:10/13/2017)... ... October 13, 2017 , ... Yisrayl Hawkins, Pastor and Overseer at ... of the most popular and least understood books in the Holy Scriptures, Revelation. The ... that have baffled scholars for centuries. Many have tossed it off as mere rubbish, ...
(Date:10/13/2017)... ... October 13, 2017 , ... Coveros, a leader ... been awarded a contract by the Center for Medicare and Medicaid Services (CMS). ... the enterprise use of Agile methodologies in a consistent and high value manner ...
(Date:10/13/2017)... ... , ... “America On The Brink”: the Christian history of the United States ... creation of published author, William Nowers. Captain Nowers and his wife, Millie, have ... thirty years in the Navy. Following his career as a naval aviator and ...
(Date:10/12/2017)... San Francisco, CA (PRWEB) , ... October 12, ... ... and Dr. Cheng, are now treating sleep apnea using cutting-edge Oventus ... sleep apnea, a serious sleep disorder characterized by frequent cessation in breathing. Oral ...
Breaking Medicine News(10 mins):